Allarity Therapeutics (ALLR) Competitors $0.99 -0.04 (-3.88%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends ALLR vs. BLRX, ATHE, BTAI, FLGC, PRPH, GLYC, SPRB, NERV, TRAW, and NRXPShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include BioLineRx (BLRX), Alterity Therapeutics (ATHE), BioXcel Therapeutics (BTAI), Flora Growth (FLGC), ProPhase Labs (PRPH), GlycoMimetics (GLYC), Spruce Biosciences (SPRB), Minerva Neurosciences (NERV), Traws Pharma (TRAW), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical preparations" industry. Allarity Therapeutics vs. BioLineRx Alterity Therapeutics BioXcel Therapeutics Flora Growth ProPhase Labs GlycoMimetics Spruce Biosciences Minerva Neurosciences Traws Pharma NRx Pharmaceuticals BioLineRx (NASDAQ:BLRX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Does the media refer more to BLRX or ALLR? In the previous week, BioLineRx's average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score. Company Overall Sentiment BioLineRx Neutral Allarity Therapeutics Neutral Do institutionals & insiders have more ownership in BLRX or ALLR? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BLRX or ALLR more profitable? Allarity Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -90.57%. BioLineRx's return on equity of -163.37% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-90.57% -163.37% -34.21% Allarity Therapeutics N/A -369.67%-100.06% Which has higher valuation and earnings, BLRX or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than BioLineRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$21.99M0.74-$60.61M-$0.22-0.92Allarity TherapeuticsN/AN/A-$11.90MN/AN/A Do analysts prefer BLRX or ALLR? BioLineRx currently has a consensus target price of $9.00, suggesting a potential upside of 4,333.50%. Given BioLineRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioLineRx is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor BLRX or ALLR? BioLineRx received 505 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 72.39% of users gave BioLineRx an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformBioLineRxOutperform Votes50672.39% Underperform Votes19327.61% Allarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Which has more volatility & risk, BLRX or ALLR? BioLineRx has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. SummaryBioLineRx beats Allarity Therapeutics on 10 of the 13 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.005.094.784.78Net Income-$11.90M$151.83M$120.23M$225.60M7 Day Performance-2.94%-2.13%-1.92%-1.23%1 Month Performance-21.43%-3.10%11.49%3.36%1 Year Performance-99.71%11.54%30.57%16.60% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics0.0459 of 5 stars$0.99-3.9%N/A-99.7%$4.39MN/A0.005News CoverageGap DownBLRXBioLineRx2.3143 of 5 stars$0.21-6.6%$9.00+4,185.7%-87.8%$16.79M$21.99M-1.0240Analyst ForecastHigh Trading VolumeATHEAlterity Therapeutics2.5794 of 5 stars$2.28-5.0%$6.00+163.2%-15.4%$16.64MN/A0.0010News CoverageBTAIBioXcel Therapeutics3.9882 of 5 stars$0.39-6.6%$5.00+1,198.4%-88.5%$16.46M$2.28M-0.1790Negative NewsGap DownHigh Trading VolumeFLGCFlora Growth3.0907 of 5 stars$1.23-5.8%$5.00+308.2%-21.6%$16.38M$64.15M0.00280Positive NewsGap DownHigh Trading VolumePRPHProPhase Labs3.1815 of 5 stars$0.69+5.2%$11.00+1,505.8%-86.8%$16.35M$12.75M-0.57130High Trading VolumeGLYCGlycoMimetics4.228 of 5 stars$0.24+2.4%$10.00+3,990.0%-89.0%$15.77M$10,000.000.0050News CoverageGap DownSPRBSpruce Biosciences3.8134 of 5 stars$0.38-0.5%$3.90+923.4%-80.5%$15.74M$10.09M-0.4120Analyst RevisionNERVMinerva Neurosciences3.467 of 5 stars$2.20-0.5%$5.00+127.3%-67.0%$15.39MN/A-5.029Analyst ForecastNews CoverageGap DownTRAWTraws PharmaN/A$4.89+5.2%N/AN/A$14.82M$230,000.000.0017Positive NewsGap UpNRXPNRx Pharmaceuticals3.2971 of 5 stars$1.20flat$32.00+2,566.7%-96.5%$14.51MN/A-0.562News CoveragePositive News Related Companies and Tools Related Companies BioLineRx Alternatives Alterity Therapeutics Alternatives BioXcel Therapeutics Alternatives Flora Growth Alternatives ProPhase Labs Alternatives GlycoMimetics Alternatives Spruce Biosciences Alternatives Minerva Neurosciences Alternatives Traws Pharma Alternatives NRx Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALLR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts